Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd has announced the successful pricing of A$650 million in convertible bonds due in 2029, with an interest rate of 2.375% per annum. The funds raised are aimed to accelerate the company’s clinical development programs, particularly in expanding the market for diagnostic imaging agents and advancing pivotal cancer therapy trials. The offering, strongly supported by global investors, also enables Telix to consider strategic mergers and acquisitions and to enhance their global supply chain and manufacturing capabilities.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
